. Author manuscript; available in PMC: 2022 Jun 1.

Published in final edited form as: Int J Gynaecol Obstet. 2021 Jan 5;153(3):533–541. doi: 10.1002/ijgo.13514

TABLE 5.

Effects of selenium supplementation on change in haemoglobin levels and HIV disease progression

Endpoint		Mean value in intervention arms^d		Mean difference (95% CI)^c	p-value^e
Endpoint		Selenium	Placebo	Mean difference (95% CI)^c	p-value^e
Hb concentration	Baseline	10.82 ± 1.43	10.55 ± 1.75	0.27 (−0.23 to 0.77)	0.653
	Endline	10.98 ± 1.44	10.90 ± 1.71	0.08 (−0.42 to 0.58)
	Within-group mean difference ± SD	−0.16 ± 2.20	−0.35 ±2.55	0.11 (−0.38 to 0.61)^b
CD4⁺ cells count (log)^a	Baseline	2.56 ±0.24	2.52 ±0.26	0.04 (−0.04 to 0.12)	0.326
	Endline	2.70 ± 0.18	2.67 ± 0.20	0.03 (−0.03 to 0.09)
	Within-group mean difference ± SD	−0.14 ± 0.13	−0.16 ±0.13	0.03 (−0.03 to 0.09)^b
Viral load (log)^a	Baseline	3.55 ± 1.61	3.84 ±1.59	−0.29 (−0.79 to 0.22)	0.230
	Endline	3.60 ±1.63	2.92 ± 1.67	−0.31 (−0.83 to 0.20)
	Within-group mean difference ± SD	0.95 ± 0.94	0.92 ± 0.76	−0.31 (−0.83 to 0.20)^b

Abbreviation: CI, confidence interval.

Values are the mean difference between the selenium and placebo arms. The mean differences, 95% CIs directly modelled the differences between repeated measures.

P value obtained from a robust parallel-group analysis with adjustment for baseline variables.

Based on linear mixed models for repeated measurements.

A base-10 scale was used.